Actively Recruiting
Study of Autologous Human Schwann Cell Transplantation for Severe Peripheral Nerve Injury Safety and Recovery
Led by W. Dalton Dietrich · Updated on 2026-09-29
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and potential harms of using a participants own Schwann cells combined with nerve auto-graft in treating severe injuries to major peripheral nerves. This study focuses on adults aged 18 to 65 who have suffered significant nerve damage such as sciatic nerve injury or brachial plexus injury. The goal is to understand the treatments effects and safety as part of supportive care after severe peripheral nerve injury. Participants will undergo a sural nerve biopsy to collect nerve segments from their leg, which are then processed to prepare a one-time dose of 80 to 100 million autologous human Schwann cells ahSC. These cells are transplanted along with a nerve auto-graft to the injured site. This is a single-group study where all participants receive the ahSC transplant. Throughout the study, participants will be monitored for up to two years to assess treatment-related adverse events and recovery progress. Researchers will evaluate motor recovery using the MRC Grading Scale, sensory recovery through pin-prick tests, and two-point discrimination tests. Safety and functional improvements will be tracked with scheduled assessments over the study period.
CONDITIONS
Brief Title
Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation in Severe Peripheral Nerve Injury (PNI)
Research Team
G
George Jimsheleishvilli, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here